HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Milestone Pharmaceuticals (NASDAQ:MIST) and maintained a price target of $25.
May 30, 2024 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Milestone Pharmaceuticals and maintained a price target of $25, indicating confidence in the company's future performance.
The reiteration of a Buy rating and a maintained price target of $25 by HC Wainwright & Co. suggests strong confidence in Milestone Pharmaceuticals' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100